← Leaderboards
Sid Ahmed Labed
Evodenovo, Inc.
$2,230,338
Attributed
$2,230,338
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,230,338 · 2
By mechanism
R44$1,975,277 · 1
R43$255,061 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Mu Opioid Receptors”
- Mark Sorenson · Nirsum Laboratories, Inc.$4,866,388
- Michael V. Voronkov · Serodopa Therapeutics Inc$2,946,808
- Daniel Levy · Phoenix Pharmalabs, Inc.$2,894,503
- Georgette Suidan · Cerevel Therapeutics, Llc$2,700,000
- Lawrence J Zana · Consegna Pharma, Inc.$2,545,988
- Ruth Huttenhain · University Of California, San Francisco$2,364,012
Research focus
Mu Opioid ReceptorsPersonsG-Protein-Coupled ReceptorsLeadOrphanPain ManagementClinical TrialsFda ApprovedInhibitorKnockout MiceOpioidOpioid Use DisorderBehavioralAnalgesicsAbsence Of Pain SensationClinically RelevantDesignEvaluationAntagonistDependenceIn VivoCaenorhabditis ElegansNeuronsPharmaceutical Chemistry
Grant awards (3)
Development of small molecule therapeutics for mitigating opioid withdrawal syndrome$1,094,320
R44 · FY2025 · DA · contact PI
Development of small molecule therapeutics for mitigating opioid withdrawal syndrome$880,957
R44 · FY2024 · DA · contact PI
Identification of Cyclic Peptide Antagonists of an Anti-Opioid G Protein-Coupled Receptor$255,061
R43 · FY2022 · DA · contact PI